Replaces Prod. #: BML-S650
Antiestrogen with anti-cancer activity. Selective protein kinase C (PKC) inhibitor and induces PKC epsilon translocation. Induces apoptosis in estrogen receptor-negative human cancer cell lines.
Product Details
| Alternative Name: | (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethanamine . citrate |
| |
| Formula: | C26H29NO . C6H8O7 |
| |
| MW: | 371.5 . 192.1 |
| |
| CAS: | 54965-24-1 |
| |
| MI: | 14: 9048 |
| |
| RTECS: | KH2387000 |
| |
| Purity: | ≥99% (Assay) |
| |
| Identity: | Determined by IR. |
| |
| Appearance: | White to off-white powder. |
| |
| Solubility: | Soluble in methanol or ethanol; very slightly soluble in water or acetone. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Is tamoxifen the Rosetta stone for breast cancer?: V.C. Jordan; J. Natl. Cancer Inst.
95, 338 (2003),
Abstract;
Tamoxifen for prevention of breast cancer: R.J. Cersosimo; Ann. Pharmacother.
37, 268 (2003),
Abstract;
Tamoxifen: a most unlikely pioneering medicine: V.C. Jordan; Nat. Rev. Drug Discov.
2, 205 (2003),
Abstract;
Update on clinical role of tamoxifen: J.R. Benson and V. Pitsinis; Curr. Opin. Obstet. Gynecol.
15, 13 (2003),
Abstract;
Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells: S. Mandlekar, et al.; Cancer Res.
60, 5995 (2000),
Abstract;
Full Text
Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes: D.A. Cameron, et al.; Eur. J. Cancer.
36, 845 (2000),
Abstract;
Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines: S. Mandlekar, et al.; Cancer Res.
60, 6601 (2000),
Abstract;
Full Text
Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review): S. Toma, et al.; Int. J. Oncol.
15, 321 (1999),
Abstract;
Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines: C.Ferlini et al.; Br. J. Cancer
79, 257 (1999),
Abstract;
Activation of nitric oxide synthase is involved in tamoxifen-induced apoptosis of human erythroleukemia K562 cells: M. Maccarrone, et al.; FEBS Lett.
434, 421 (1998),
Abstract;
Antagonist effect of insulin-like growth factor I on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-xL: S.A. Toms et al.; J. Neurosurg.
88, 884 (1998),
Abstract;
Recent advances in understanding the molecular mechanisms of tamoxifen action: Z.Y. Friedman; Cancer Invest.
16, 391 (1998),
Abstract;
Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal: R.E. Favoni & A. de Cupis; TIPS
19, 406 (1998), (Review),
Abstract;
Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells: Y. Lavie et al.; Int. J. Cancer.
77, 928 (1998),
Abstract;
Genomic effects of tamoxifen: J.A. Kellen; Anticancer Res.
16, 3537 (1996),
Abstract;
Tamoxifen: teaching an old drug new tricks?: D.J. Grainge & J.C. Metcalfe; Nat. Med.
2, 381 (1996), (Review),
Abstract;
Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines: W.T. Couldwell, et al.; FEBS Lett.
345, 43 (1994),
Abstract;
Signalling targets for anticancer drug development: G. Powis; TIPS
12, 188 (1991), (Review),
Abstract;
Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells: M. Issandou, et al.; Cancer Res.
50, 5845 (1990),
Abstract;
Inhibition of protein kinase C by tamoxifen: C.A. O'Brian, et al.; Cancer Res.
45, 2462 (1985),
Abstract;
